Drug Trial Radar · NCT05142189
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Jun 17, 2022
Primary completion
Feb 2030
Study completion Nov 2031
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, osimertinib, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), rearranged during transfection (RET) TKIs, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, an anti-human epidermal growth factor receptor 3 (HER3) antibody conjugated to a topoisomerase I inhibitor or a bispecific antibody for programmed death ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC). The study will comprise several cohorts for dose confirmation in monotherapy as well as in combinations of BNT116 as mentioned above. The study will enroll participants with NSCLC in advanced or metastatic stage in Cohorts 1 to 4 and Cohorts 7 to 10, unresectable NSCLC Stage III in Cohorts 5 and 11, resectable NSCLC of Stage II and III in Cohort 6, advanced/metastatic epidermal growth factor receptor (EGFR)-mutant NSCLC in Cohort EGFR, and advanced/metastatic ALK rearranged or RET rearranged NSCLC in Cohort ALK/RET. Cohort EGFR and Cohort ALK/RET will enroll only at selected sites in the US.
Conditions
- Non-Small Cell Lung Cancer
Interventions
BNT116Biological
Intravenous injection
CemiplimabBiological
Intravenous infusion
DocetaxelDrug
Intravenous infusion
CarboplatinDrug
Intravenous infusion
PaclitaxelDrug
Intravenous infusion
BNT316Biological
Intravenous infusion
anti-B7-H3 antibody conjugated to topoisomerase I inhibitorBiological
Intravenous infusion
anti-HER3 antibody conjugated to topoisomerase I inhibitorBiological
Intravenous infusion
Bispecific antibody for PD-L1 and VEGF-ABiological
Intravenous infusion
OsimertinibBiological
Oral
ALK-inhibitor or RET-inhibitorBiological
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohorts 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, EGFR and ALK/RET: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation PeriodTime frame: From first dose of IMP up to 21 days
- Cohorts 1 to 11, EGFR and ALK/RET: Occurrence of Treatment-Emergent Adverse Events (TEAEs) Reported by Relationship, Seriousness, and GradeTime frame: up to 27 months
- Cohort 6 only: Occurrence of Post-Surgical Adverse Events (AEs) Related to BNT116 and CemiplimabTime frame: up to 27 months
- Cohort 6 only: Occurrence of Treatment-Related Delays to Surgery More Than 9 weeks Post the Last Dose of Neo-Adjuvant TreatmentTime frame: up to 6 months
Locations
45 sites in 8 countries. Site status is shown where the registry gives one.
University of Kentucky Chandler Medical Center
Lexington, Kentucky · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Scientia Clinical Research
Randwick, New South Wales, Australia · Recruiting
Royal North Shore Hospital
Sydney, New South Wales, Australia · Recruiting
Cancer Research SA
Adelaide, South Australia, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Recruiting
Universitätsklinikum Köln
Cologne, Germany · Recruiting
Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)
Frankfurt, Germany · Recruiting
University Medical Center Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR
Mainz, Germany · Recruiting
ICON-PRA Budapest, Fázis 1 Vizsgálóhely
Budapest, Hungary · Completed
Semmelweis Egyetem ÁOK Belgyógyászati és Onkológiai Klinika
Budapest, Hungary · Completed
National Institute of Oncology
Budapest, Hungary · Recruiting
Clinexpert Ltd
Gyöngyös, Hungary · Recruiting
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland · Recruiting
Warminsko Mazurskie Centrum Chorob Pluc w Olsztynie
Olsztyn, Poland · Recruiting
NZOZ Medpolonia Sp. Z o.o
Poznan, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Warsaw, Poland · Withdrawn
Institut Catala d'Oncologia Badalona, Hospital Germans Trias I Pujol
Badalona, Spain · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
MD Anderson Cancer Center
Madrid, Spain · Recruiting
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain · Recruiting
START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC)
Madrid, Spain · Recruiting
Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) - Hospital Clinico Universitario (University Clinical Hospital)
Santiago de Compostela, Spain · Recruiting
Hospital Universitario Virgen Macarena
Seville, Spain · Recruiting
Hospital Universitario y Politecnico La Fe
Valencia, Spain · Recruiting
Adana City Training and Research Hospital
Adana, Turkey (Türkiye) · Recruiting
Haceteppe Hospital
Ankara, Turkey (Türkiye) · Recruiting
Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
Ankara, Turkey (Türkiye) · Recruiting
Ankara City Hospital
Ankara, Turkey (Türkiye) · Recruiting
Koc University Hospital
Istanbul, Turkey (Türkiye) · Recruiting
University Medical Faculty Oncology Institute
Istanbul, Turkey (Türkiye) · Recruiting
Yeditepe University
Istanbul, Turkey (Türkiye) · Recruiting
Ege University School of Medicine Tulay Aktas Oncology Hospital
Izmir, Turkey (Türkiye) · Recruiting
Dokuz Eylul Medical School
Izmir, Turkey (Türkiye) · Completed
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.